[{"orgOrder":0,"company":"Purisys LLC","sponsor":"CNBX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"RCC-33","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Purisys LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Purisys LLC \/ Purisys","highestDevelopmentStatusID":"4","companyTruncated":"Purisys LLC \/ Purisys"}]

Find Clinical Drug Pipeline Developments & Deals by Purisys LLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Under the agreement, Purisys will support an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA r...

                          Brand Name : RCC-33

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 04, 2021

                          Lead Product(s) : RCC-33

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : CNBX Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Noramco